Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 19/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 17/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1943904 | 0.93 | CCR2 (0.76) | CCR2KCNH2CYP3A4CYP2D6 | |
| SCHEMBL1944137 | 0.93 | CCR2 (0.76) | CCR2KCNH2CYP3A4CYP2D6 | |
| SCHEMBL1942076 | 0.93 | CCR2 (0.76) | CCR2KCNH2CYP3A4CYP2D6 | |
| SCHEMBL1942965 | 0.91 | CCR2 (0.83) | CCR2KCNH2CYP3A4CYP2D6 | |
| SCHEMBL1943590 | 0.90 | CCR2 (1.00) | CCR2KCNH2CYP3A4CYP2D6 | |
| SCHEMBL1942680 | 0.89 | CCR2 (0.79) | CCR2KCNH2CYP3A4CYP2D6 | |
| SCHEMBL1942030 | 0.88 | CCR2 (1.00) | CCR2KCNH2CYP3A4CYP2D6 | |
| SCHEMBL1943406 | 0.88 | CCR2 (1.00) | CCR2KCNH2CYP3A4CYP2D6 | |
| SCHEMBL1945718 | 0.88 | CCR2 (1.00) | CCR2KCNH2CYP3A4CYP2D6 | |
| SCHEMBL1943536 | 0.88 | CCR2 (0.79) | CCR2KCNH2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710224-B2 | Heterocyclic compounds as CCR2B antagonists | ASTRAZENECA AB (SE) | 2014-04-29 | — | — | US | disclosed |
| US-20140038978-A1 | HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS | ASTRAZENECA AB (SE) | 2014-02-06 | — | — | US | disclosed |
| US-20140038978-A1 | HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS | ASTRAZENECA AB (SE) | 2014-02-06 | — | — | US | disclosed |
| US-20140038978-A1 | HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS | ASTRAZENECA AB (SE) | 2014-02-06 | — | — | US | disclosed |
| US-20120264762-A1 | Heterocyclic Compounds as CCR2 Antagonists | ASTRAZENECA AB (SE) | 2012-10-18 | — | — | US | disclosed |
| US-20120264762-A1 | Heterocyclic Compounds as CCR2 Antagonists | ASTRAZENECA AB (SE) | 2012-10-18 | — | — | US | disclosed |
| US-20120264762-A1 | Heterocyclic Compounds as CCR2 Antagonists | ASTRAZENECA AB (SE) | 2012-10-18 | — | — | US | disclosed |
| US-20110136820-A1 | Heterocyclic Compounds as CCR2 Antagonists | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | US | disclosed |
| US-20110136820-A1 | Heterocyclic Compounds as CCR2 Antagonists | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | US | disclosed |
| US-20110136820-A1 | Heterocyclic Compounds as CCR2 Antagonists | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | US | disclosed |
| US-7906645-B2 | Heterocyclic compounds as ccr2b antagonists | ASTRAZENECA AB (SE) | 2011-03-15 | — | — | US | disclosed |
| US-7906645-B2 | Heterocyclic compounds as ccr2b antagonists | ASTRAZENECA AB (SE) | 2011-03-15 | — | — | US | disclosed |
| US-7906645-B2 | Heterocyclic compounds as ccr2b antagonists | ASTRAZENECA AB (SE) | 2011-03-15 | — | — | US | disclosed |
| US-20090099156-A1 | Heterocyclic Compounds as Ccr2b antagonists | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099156-A1 | Heterocyclic Compounds as Ccr2b antagonists | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264762-A1 | Heterocyclic Compounds as CCR2 Antagonists | CCR2, CCR3, CXCR2 | CCR2 1/4885KCNH2 2034/4885CYP3A4 1406/4885 |
| US-20110136820-A1 | Heterocyclic Compounds as CCR2 Antagonists | CCR2, CCR3, CXCR2 | CCR2 1/4885KCNH2 2034/4885CYP3A4 1406/4885 |
| US-20140038978-A1 | HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS | CCR2, CCR3, CXCR2 | CCR2 1/4885KCNH2 2490/4885CYP3A4 1608/4885 |
| US-20090099156-A1 | Heterocyclic Compounds as Ccr2b antagonists | CCR2, CCR3, CXCR2 | CCR2 1/4885KCNH2 2418/4885CYP3A4 1686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.